Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Diabetes Dialogue: Prescribing Tirzepatide, Biosimilar Insulins, & Misdiagnosis of T1D

Diabetes Dialogue: Prescribing Tirzepatide, Biosimilar Insulins, & Misdiagnosis of T1D

FromDiabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives


Diabetes Dialogue: Prescribing Tirzepatide, Biosimilar Insulins, & Misdiagnosis of T1D

FromDiabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

ratings:
Length:
24 minutes
Released:
Jun 24, 2022
Format:
Podcast episode

Description

In this edition of Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives our hosts discuss the experiences of their prescribing tirzepatide (Mounjaro) to patients and what types of issues patients have encountered, the prospect of new biosimilar insulins that may be coming to the market, and the misdiagnosis of type 1 diabetes in adult patients. 
Released:
Jun 24, 2022
Format:
Podcast episode

Titles in the series (94)

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Drs. Diana Isaacs and Natalie Bellini aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care. A video version of each episode is available at http://HCPLive.com/Clinical/Endocrinology. Please direct podcast-related inquiries to PCampbell@MJHLifesciences.com. Editor's note: Episodes predating January 2023 were hosted by Endocrinology Network. Episodes predating March 2022 were titled The Endocrine Outlook.